CANC
Tema Oncology ETF
NAV as of
4 Week: 33.19 - 35.98
52 Week: 20.98 - 35.98
Latest Closing Price
34.59
Premium / Discount
0.23
Expense Ratio
0.75%
Investment Objective
The investment seeks to provide long-term growth. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
Main Fund Characteristics
Performance
| Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
|---|---|---|---|
| YTD | 42.48 | 1.63 | 26.04 |
| 1 Day | 0.14 | 0.00 | 0.00 |
| 1 Week | -1.30 | 2.99 | -0.43 |
| 1 Month | 4.42 | 5.72 | 0.77 |
| 3 Months | 26.27 | 10.45 | 2.51 |
| 6 Months | 32.40 | 15.37 | 2.11 |
| 1 Year | 35.56 | 25.69 | 1.38 |
| 2 Years | 39.77 | 32.72 | 1.22 |
| 3 Years | 0.00 | 0.00 | 0.00 |
| 5 Years | 0.00 | 0.00 | 0.00 |
| 10 Years | 0.00 | 0.00 | 0.00 |
Price History
Annual Performance Return
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
| Price (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | -4.5225 |
| Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
| Rank | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 88.0000 |
Dividend Frequency
Lastest Dividend
| Ex Date | Payment Date | Dividend Payout per unit |
|---|---|---|
| 09/12/2025 | 10/12/2025 | 0.0196 |
| 10/12/2024 | 11/12/2024 | 0.7283 |
Portfolio Data
Total Number of Holdings: 56
Number of Bond Holdings: 0
Number of Equity Holdings: 54
Total Market Value: 107,254,221
Portfolio Composition
Top 10 Holdings
| % Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
|---|---|---|---|---|---|
| 1 | Revolution Medicines Inc Ordinary Shares | 6.3297 | 85,336 | 1,100 | 6,699,729 |
| 2 | Eli Lilly and Co | 5.0781 | 5,325 | 68 | 5,374,948 |
| 3 | AstraZeneca PLC | 4.4489 | 25,858 | 332 | 4,709,011 |
| 4 | BridgeBio Pharma Inc | 4.3736 | 62,503 | 804 | 4,629,285 |
| 5 | Novartis AG Registered Shares | 4.1828 | 33,203 | 428 | 4,427,345 |
| 6 | Roche Holding AG ADR | 3.9954 | 84,546 | 1,088 | 4,228,991 |
| 7 | Genmab AS ADR | 3.9392 | 129,085 | 1,664 | 4,169,446 |
| 8 | Cogent Biosciences Inc | 3.7447 | 98,992 | 1,276 | 3,963,640 |
| 9 | Nuvalent Inc Class A | 3.3972 | 33,951 | 436 | 3,595,750 |
| 10 | Bristol-Myers Squibb Co | 3.3379 | 69,004 | 888 | 3,533,005 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
| Size | % of portfolio |
|---|---|
| Giant | 22.79 |
| Large | 18.14 |
| Medium | 16.82 |
| Small | 19.52 |
| Micro | 20.33 |
Equity Style Box Breakdown
| 0 | 0 | 0 | Large |
| 0 | 0 | 0 | Mid |
| 0 | 0 | 0 | Small |
| Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
16.0487
Price/Book*
5.9271
Price/Sales*
5.0704
Price/Cash Flow*
12.4661
Dividend Yield*
0.9872
Growth Measures
Long-Term Earnings
6.4395
Historical Earnings
14.4465
Sales Growth
7.7632
Cash-Flow Growth
4.7692
Book-Value Growth
-0.3734
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
| Detail | Value |
|---|---|
| Average Effective Duration | 0 |
| Average Effective Maturity (Years)* | 0 |
| Average Credit Quality | 0 |
| Average Weighted Coupon* | 0 |
| Average Weighted Price* | 0 |
Bond Style Box Breakdown
| 0 | 0 | 0 | High | Quality |
| 0 | 0 | 0 | Med | |
| 0 | 0 | 0 | Low | |
| Ltd | Mod | Ext | ||
| Interest-Rate Sensitivity | ||||
Credit Quality
| Type | % Bonds |
|---|---|
| N.A | |
Bond Sector
Bond Maturity
| % Bonds | |
|---|---|
| N.A | |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.
